Lutetium-177 [177Lu]Lu-prostate-specific membrane antigen (PSMA)-617 has established itself as a valuable life-prolonging treatment with high response rates in metastatic castration-resistant prostate cancer.1 [177Lu]Lu-PSMA-617 has shown superior radiographic progression-free survival and health-related quality of life compared with other approved agents.2,3